Company
Every investor coverage indicates participated in a round EMA raised.
Companies EMA acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming EMA. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech Certa Therapeutics reported encouraging Phase 2 results for its scleroderma drug FT011 at a US rheumatology meeting, with safety confirmed and a pivotal trial planned.
Australian biotech Certa Therapeutics reports Phase 2 scleroderma trial results for FT011 at a US rheumatology meeting, showing efficacy and safety, with a pivotal study planned.